Wednesday, June 3, 2020

Investor Ideas #Potcasts, #Cannabis News and #Stocks on the Move; Episode 422 (OTC: $CSUI) (NASDAQ: $HUGE) (TSX: $RIV.TO) (OTCQB: $CBDY) (TSX: $HEXO.TO) (OTC: $CURR)


Investor Ideas #Potcasts, #Cannabis News and #Stocks on the Move; Episode 422 (OTC: $CSUI) (NASDAQ: $HUGE) (TSX: $RIV.TO) (OTCQB: $CBDY) (TSX: $HEXO.TO) (OTC: $CURR)

Delta, Kelowna, BC, June 3, 2020 (Investorideas.com Newswire) www.Investorideas.com, a global news source covering leading sectors including marijuana and hemp stocks and its potcast site, www.potcasts.ca  release today’s podcast edition of  cannabis news and stocks to watch plus insight from thought leaders and experts.

Listen to the podcast:




Today’s podcast overview/transcript:

Good afternoon and welcome to another episode of Investorideas.com "Potcast" featuring cannabis news, stocks to watch as well as insights from thought leaders and experts.

Today’s podcast is sponsored by Cannabis Suisse Corp. (OTC: CSUI)a research & development company licensed under Swiss Cannabis and tobacco regulations to cultivate and sell cannabis. The Company's facilities for producing cannabis are based in Zurich.

The Company grows high quality, organic cannabis with sustainable, all-natural principles. Cannabis Suisse products are laboratory tested to ensure the end users have access to a standardized, safe and consistent product.

In today’s podcast we will be looking at a few public company announcements.

FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) had a “huge” run today, up nearly 180%, after having announced that the U.S. Food and Drug Administration (FDA) has given the company permission to submit an Investigational New Drug Application (IND) for the use of FSD-201 (ultramicronized palmitoylethanolamide, or ultramicronized PEA)  to treat COVID-19, the disease caused by the SARS-CoV-2 virus. Severe COVID-19 is characterized by an over-exuberant inflammatory response that may lead to a cytokine storm and ultimately death. FSD Pharma is focused on developing FSD-201 for its anti-inflammatory properties to avoid the cytokine storm associated with acute lung injury in hospitalized COVID-19 patients.

"FDA's permission to design a proof-of-concept study in COVID-19 patients evaluating clinical doses of FSD-201 is a paradigm shift for FSD Pharma and is the result of outstanding work conducted by Dr. Edward Brennan, President FSD BioSciences, and his team," said Raza Bokhari, MD, Executive Co-Chairman & CEO. "We contacted the FDA in late-March 2020 after becoming aware that several Italian physicians and scientists were advocating for use of ultramicronized PEA for patients suffering from symptoms of COVID-19, based on the drug's mechanism of action as a potent and safe anti-inflammatory agent that reduces the production of pro-inflammatory cytokines. Numerous studies over the past 40 years also validate the efficacy and safety of ultramicronized PEA in the treatment and prophylactic effects in respiratory infections. These studies also pointed out that the ease of application of PEA offers the possibility to have a quick therapeutic answer ready in case of a flu epidemic."

Based on the FDA feedback received to date, we expect the trial will be a randomized, controlled, double-blind, U.S. multicenter study to assess the efficacy and safety of FSD-201 dosed 600mg or 1200mg twice-daily plus standard of care (SOC) versus SOC alone in symptomatic patients with clinical presentation compatible with COVID-19. Eligible patients will present with symptoms consistent with influenza/coronavirus signs (fever, dry cough, malaise, difficulty breathing) and/or newly documented positive COVID-19 disease.

The primary endpoint is to determine if FSD-201 plus SOC provides a significant improvement in clinical status (i.e., shorter time to symptom relief). Key secondary objectives include determining if FSD-201 plus SOC demonstrates additional benefit in terms of safety, objective assessments such as length of time to normalization of fever, length of time to improvement of oxygen saturation and length of time to clinical progression including time to mechanical ventilation or hospitalization, and length of hospital stay. The exploratory endpoint is cytokine clearance as measured by Enzyme Linked Immunosorbent Assay (ELISA).

The treatment period is expected to be 14 days.  All patients who experience clinical benefit are expected to continue to receive their assigned treatment until study completion.

Canopy Rivers Inc. (TSX: RIV) (OTC: CNPOF), a venture capital firm specializing in cannabis, today released its audited consolidated financial statements for the fiscal year ended March 31, 2020 and management's discussion and analysis for the three and twelve months ended March 31, 2020.

"The global economic uncertainty brought on by COVID-19 capped off a volatile and challenging year for the cannabis sector. Despite these challenges, I am pleased with what our team achieved last year. However, we were not immune to this volatility, and following a strategic and operational review of our business, we recently announced a number of changes aimed at strengthening our financial discipline and positioning Canopy Rivers for sustained success moving forward," said NarbĂ© Alexandrian, President and CEO of Canopy Rivers. "Reflecting on the past year, there were several significant achievements that make me optimistic for fiscal year 2021. First, our portfolio companies reached new milestones, including the licensing of PharmHouse, the expansion of TerrAscend's U.S. operations, and ZeaKal's successful trials of its PhotoSeed™ technology. Second, our graduation to the TSX and the launch of our Strategic Advisory Board signalled our company's continued maturation. Finally, we made four new investments, including two in ag-tech, which we believe is a critical component of the value chain that is poised to disrupt the cannabis sector."

"While headwinds persist, we remain positive as we evaluate new opportunities that we believe will ultimately create value for our shareholders and help build the cannabis industry of tomorrow," added Alexandrian.

"Looking back on FY 2020, it is clear that cannabis companies encountered challenging conditions in the capital markets over those 12 months, and the impact of this shows in our financial results for the fiscal year," said Eddie Lucarelli, CFO of Canopy Rivers. "However, we believe that this is more of a function of the slower-than-expected pace of development of the cannabis economy, rather than its long-term potential, which we continue to believe is significant. Based on our available cash resources and deep sector insights, we believe we are well-positioned to capitalize on the current market conditions and strengthen our portfolio of cannabis disruptors."

TARGET GROUP INC. (OTCQB: CBDYannounced that its wholly owned subsidiary, Canary RX Inc. has entered into an agreement to form a Joint Venture Partnership with THRIVE CANNABIS INC. in Norfolk County, ON for the production of premium craft cannabis.

The terms of the 5 year definitive agreement have Target and Thrive each with a 50% ownership of the JV. Target, via its wholly owned subsidiary Canary RX Inc. will permit Thrive to produce premium craft grown cannabis in 7 of its 8, 2300 square foot growing rooms within its existing 44,000 sq. ft. licenced cultivation facility in Norfolk County, ON. In addition, Thrive will maintain and supervise the staff on their proprietary methods of cultivation that it currently utilizes from its production in Canada. Operations within the facility are expected to begin immediately.

This partnership is anticipated to increase the initial production yields within the Canary RX facility and will encompass stronger cultivation management led by an already proven team. Once operational, the JV will begin producing premium craft cannabis for both Target and Thrive, to supply existing distribution networks in Canada. The JV will, additionally, utilize formulations from both parties in Canada as well as manufacture proprietary branded products that both parties plan to distribute throughout their respective supply chains.

"Moving forward with Thrive Cannabis in the form of this JV allows us to execute our growth strategy more quickly and efficiently. Their knowledge in maximising the growth of cannabis in our Canary Rx facility and development of genetics is next to none. We are very excited with the Thrive partnership and experience their team brings" said Tony Zarcone, Target Group's CEO.

"This is a world class asset to take on under our management that adds substantial capacity for the cultivation of premium indoor flower. We could not be happier to be partnering with Canary RX for the mutual benefit of our organizations and shareholders," said Geoff Hoover, Thrive CEO.

The JV will also look to manufacture white label products for other licensed producers throughout Canada, and it is currently in talks with several potential customers to produce other value-added cannabis products such as tinctures, topicals, pre-rolls, food products and formulated bulk THC/CBD oil.

HEXO Corp (TSX: HEXO) (NYSE: HEXOannounced the launch of a new 30 gram medical flower format for its popular high-THC strain Tsunami under HEXO medical cannabis.

HEXO has been dedicated to providing Canadian clients high quality medical cannabis since 2015. A year ago, the Company updated its medical packaging to comply with the Cannabis Regulations, resulting in smaller product formats.  HEXO is proud to launch a new 30 g format offered in a resealable, odour-proof and child-resistant pouch.

“We know our medical clients have been waiting for this opportunity to purchase a higher volume of cannabis without excess packaging,” said HEXO CEO and co-founder Sebastien St-Louis. "Our Tsunami flower benefits from enhanced humidity controls for maximum freshness and to promote ideal bud density.”

The move to a larger format and a new type of packaging is an important step on HEXO’s sustainability journey and provides medical clients with a more discreet option for high volume orders.

“At HEXO, we have a long history of medical cannabis. We offer our clients free shipping and absorb the federal excise tax on their behalf,” added St-Louis. “This product is being offered exclusively to medical clients and we look forward to continuing to roll out additional strains in this format soon.”

CURE Pharmaceutical (OTC: CURR), an innovative drug delivery and development company, announced today a collaboration with PMI, a subsidiary of Factoria Bogar in Guadalajara, Mexico. PMI will have access to CURE’s innovative drug delivery platform, CUREform™ for its drug formulation, as well as become its distribution partner in Mexico for CURE’s wellness products, such as its vitamin D supplement, sleep and CBD combination products.

“This collaboration enables us to reach new markets with our suite of wellness products as well as prompt innovation with new drug formulations and conduct valuable patient studies on drug efficacy,” said Rob Davidson, CEO of CURE. “This is a valuable partnership from both a revenue perspective as well as an opportunity to expand product offerings and research collaborations.”

PMI will be distributing CURE’s wellness products throughout Mexico, including its weekly vitamin D supplement and sleep aid delivered using CUREfilm® technology. The weekly vitamin D supplements provides 50,000 IU of vitamin D3 to reduce risk of infections. CURE sleep strips contain a soothing blend of melatonin, naturally occurring amino acids and beneficial vitamins that promote fast-acting, balanced sleep patterns for a deep, restful slumber and a rejuvenated awakening.

“Staying healthy and getting enough sleep are at the top of everyone’s mind during these very stressful days and CURE’s wellness products are welcome addition to our offerings,” said Mauricio Villanueva, CEO of PMI and Factoria Bogar. “Incorporating CURE’s drug delivery platform into our future drug and wellness formulations will create new opportunities to differentiate ourselves in the market.”

The PMI collaboration will include several development initiatives with its proprietary prebiotic product from Agave in combination with CBD that leverages the CUREform™ novel delivery platform for treatment of multiple GI indications. With CUREform, the delivery of cannabinoids is easier and more effective because it offers increased bioavailability, simple precision of dosing and greater palatability. There are patient studies planned for Mexico to improve drug efficacy with CBD and prebiotics.


Once again, today’s podcast was sponsored by Cannabis Suisse Corp. (OTC: CSUI)a research & development company licensed under Swiss Cannabis and tobacco regulations to cultivate and sell cannabis. The Company's facilities for producing cannabis are based in Zurich.
The Company grows high quality, organic cannabis with sustainable, all-natural principles. Cannabis Suisse products are laboratory tested to ensure the end users have access to a standardized, safe and consistent product.
Investor ideas reminds all listeners to read our disclaimers and disclosures on the
Investorideas.com website and this podcast is not an
ucts or services or securities. Investors are reminded all investment involves risk and possible loss of investment   

Learn more about our cannabis podcasts at https://www.investorideas.com/Audio/Potcasts.asp


To hear more Investorideas.com podcasts visit: https://www.investorideas.com/Audio/.
Investorideas.com podcasts are also available on iTunes,  Spotify, Google Play Music, Stitcher, Spreaker,   YouTube via Spreaker,  iHeartradio and Tunein.

Potcasts is now a certified word mark Trademark on the blockchain through Cognate, Inc. CM Certification-Registration Number: 10468217708

About Investorideas.com - News that Inspires Big Investing Ideas
Investorideas.com is a recognized news source publishing third party news, research and original financial content. Learn about investing in stocks and sector trends with our news alerts, articles, podcasts and videos, looking at cannabis, crypto, AI and IoT, mining, sports biotech, water, renewable energy and more. Investor Idea’s original branded content includes the following podcasts and columns : Crypto Corner , Play by Play sports and stock news column, Investor Ideas Potcasts Cannabis News and Stocks on the Move podcast and column,  Cleantech and Climate Change , Exploring Mining  the AI Eye .
Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Contact management and IR of each company directly regarding specific questions. Disclosure: CSUI is a paid news and social media client
More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ and tickertagstocknews.com Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp

Investor Ideas does not condone the use of cannabis except where permissible by law. Our site does not possess, distribute, or sell cannabis products.


Download our Mobile App for iPhone and Android 

Contact Investorideas.com
800 665 0411



Get more Cannabis Stock Investor Ideas – news, articles, podcasts and stock directory



#CBD #Stocks in the News: GDET (OTC: $GDET) Engages Online Marketing Firm to for #ECommerce CBD Store; @GDEntertainmen4


#CBD #Stocks in the News: GDET (OTC: $GDET) Engages Online Marketing Firm to for #ECommerce CBD Store; @GDEntertainmen4

FORT LEE, NJ, June 3, 2020– ( Investorideas.com newswire) – Breaking cannabis/CBD  stock news - GD Entertainment and Technology (OTC: GDET) (“GDET” or the “Company”), an emerging leader in the CBD products marketplace, is pleased to report that the Company has engaged EDM Media LLC (“EDM”), a leader in digital marketing and branding strategies, to aggressively drive web traffic to the Company’s CBD e-commerce portal (TheGreeneryCo.com). Increased traffic through the online store is one of the core goals in the Company’s recently launched multi-pronged marketing and brand development strategy.


The team at EDM has helped hundreds of clients reach their digital marketing and branding goals over the past two decades.

“We have both pricing and product quality advantages to work with, and we are selling to a rapidly growing marketplace, but the x-factor is really about cultivating a strong river of potential customers aware of those advantages,” remarked Anil Idnani, CEO of GDET. “We feel we are in great hands with EDM.”

Driving traffic to the The Greenery store represents an initial step in a wider marketing and brand development strategy now underway at GDET. The Company has recently divested complex operations involved in cryptocurrency mining, Bitcoin ATM, and CBD physical store sales segments, freeing up resources that will be focused exclusively on maximizing the growth potential of its online CBD sales segment.

About GDET
GD Entertainment & Technology, also known as GDET, focuses on high growth industries to fulfill a diverse selection of premium products nationwide. The company is now solely focused on building the #1 online source for high-quality CBD-based products at TheGreeneryCo.com.

Safe Harbor Provision Cautionary statement for purposes of the "Safe Harbor" provisions of the Private Securities Litigation Reform Act of 1995: Information in this news release contains forward-looking statements that involve risks, uncertainties and assumptions. If such risks or uncertainties materialize or such assumptions prove incorrect, the results of the Company and its consolidated subsidiaries could differ materially from those expressed or implied by such forward-looking statements and assumptions. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. Risks, uncertainties and assumptions include the execution and performance of contracts by the Company and its customers, suppliers and partners. Please also review GD Entertainment and Technology annual and quarterly financials for a more complete discussion of risk factors. The Company disclaims any obligation to update or revise statements contained in this news release based on new information or otherwise. This communication shall not constitute an offer to sell or the solicitation of an offer to buy securities nor shall there be any sale of these securities in any state in which such solicitation or sale would be unlawful prior to registration or qualification of these securities under the laws of any such state.

Contact:
GD Entertainment and Technology
732-851-3756
anil@gdet.co
www.gdet.co
1 Bridge Plaza
2nd Floor
Fort Lee, NJ 07024

Paid news Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Contact management and IR of each company directly regarding specific questions. Disclosure : this news release featuring  OTC: GDET is a paid for news release on Investorideas.com  https://www.investorideas.com/News-Upload/ More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ and tickertagstocknews.com  Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp

About Investorideas.com

Sign up for free stock news alerts at Investorideas.com

Get more Cannabis Stock Investor Ideas - news, articles, podcasts and stock directories




Tuesday, June 2, 2020

Investorideas.com - CBD Stock News: AMERI Holdings (NASDAQ: $AMRH) Amalgamation Partner Jay Pharma Reports IRB Approval For Testing Proprietary CBD Formulation In Brain Cancer

Investorideas.com - CBD Stock News: AMERI Holdings (NASDAQ: $AMRH) Amalgamation Partner Jay Pharma Reports IRB Approval For Testing Proprietary CBD Formulation In Brain Cancer

#CBD #Stock Breaking News - GDET (OTC: $GDET) Engages Leading Online Marketing Firm to Drive Traffic and Sales at The Greenery Online CBD Store; @GDEntertainmen4

#CBD #Stock Breaking News - GDET (OTC: $GDET) Engages Leading Online Marketing Firm to Drive Traffic and Sales at The Greenery Online CBD Store; @GDEntertainmen4


FORT LEE, NJ, June 2, 2020– Investorideas.com newswire) – Breaking cannabis/CBD  stock news - GD Entertainment and Technology (OTC: GDET) (“GDET” or the “Company”), an emerging leader in the CBD products marketplace, is pleased to report that the Company has engaged EDM Media LLC (“EDM”), a leader in digital marketing and branding strategies, to aggressively drive web traffic to the Company’s CBD e-commerce portal (TheGreeneryCo.com). Increased traffic through the online store is one of the core goals in the Company’s recently launched multi-pronged marketing and brand development strategy.


The team at EDM has helped hundreds of clients reach their digital marketing and branding goals over the past two decades.

“We have both pricing and product quality advantages to work with, and we are selling to a rapidly growing marketplace, but the x-factor is really about cultivating a strong river of potential customers aware of those advantages,” remarked Anil Idnani, CEO of GDET. “We feel we are in great hands with EDM.”

Driving traffic to the The Greenery store represents an initial step in a wider marketing and brand development strategy now underway at GDET. The Company has recently divested complex operations involved in cryptocurrency mining, Bitcoin ATM, and CBD physical store sales segments, freeing up resources that will be focused exclusively on maximizing the growth potential of its online CBD sales segment.

About GDET
GD Entertainment & Technology, also known as GDET, focuses on high growth industries to fulfill a diverse selection of premium products nationwide. The company is now solely focused on building the #1 online source for high-quality CBD-based products at TheGreeneryCo.com.
Safe Harbor Provision Cautionary statement for purposes of the "Safe Harbor" provisions of the Private Securities Litigation Reform Act of 1995: Information in this news release contains forward-looking statements that involve risks, uncertainties and assumptions. If such risks or uncertainties materialize or such assumptions prove incorrect, the results of the Company and its consolidated subsidiaries could differ materially from those expressed or implied by such forward-looking statements and assumptions. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. Risks, uncertainties and assumptions include the execution and performance of contracts by the Company and its customers, suppliers and partners. Please also review GD Entertainment and Technology annual and quarterly financials for a more complete discussion of risk factors. The Company disclaims any obligation to update or revise statements contained in this news release based on new information or otherwise. This communication shall not constitute an offer to sell or the solicitation of an offer to buy securities nor shall there be any sale of these securities in any state in which such solicitation or sale would be unlawful prior to registration or qualification of these securities under the laws of any such state.

Contact:
GD Entertainment and Technology
732-851-3756
anil@gdet.co
www.gdet.co
1 Bridge Plaza
2nd Floor
Fort Lee, NJ 07024

Paid news Disclaimer/DisclosureInvestorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Contact management and IR of each company directly regarding specific questions. Disclosure : this news release featuring  OTC: GDET is a paid for news release on Investorideas.com  https://www.investorideas.com/News-Upload/ More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ and tickertagstocknews.com  Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp

About Investorideas.com

Sign up for free stock news alerts at Investorideas.com


Get more Cannabis Stock Investor Ideas - news, articles, podcasts and stock directories



Monday, June 1, 2020

Investorideas.com - Cannabis Stock News: HEXO's (TSX: $HEXO.TO) (NYSE: $HEXO) Belleville facility receives its sales license

Investorideas.com - Cannabis Stock News: HEXO's (TSX: $HEXO.TO) (NYSE: $HEXO) Belleville facility receives its sales license

Get the latest Cannabis and Hemp stock news from www.investorideas.com

Investorideas.com - Cannabis / Beverage Stock News: Hill Street (TSXV: BEER) Reports 5% Revenue Growth YTD In Spite of Pandemic Lockdown

Investorideas.com - Cannabis / Beverage Stock News: Hill Street (TSXV: BEER) Reports 5% Revenue Growth YTD In Spite of Pandemic Lockdown

Investor Ideas #Potcasts, #Cannabis News and #Stocks on the Move; Episode 421 (OTC: $CSUI) (CSE: $OILS.C) (TSX: $VLNS.TO) (OTCQX: $CANN)


Investor Ideas #Potcasts, #Cannabis News and #Stocks on the Move; Episode 421 (OTC: $CSUI) (CSE: $OILS.C) (TSX: $VLNS.TO) (OTCQX: $CANN)



Delta, Kelowna, BC, June 1, 2020 (Investorideas.com Newswire) www.Investorideas.com, a global news source covering leading sectors including marijuana and hemp stocks and its potcast site, www.potcasts.ca  release today’s podcast edition of  cannabis news and stocks to watch plus insight from thought leaders and experts.

Listen to the podcast:



Today’s podcast overview/transcript:

Good afternoon and welcome to another episode of Investorideas.com "Potcast" featuring cannabis news, stocks to watch as well as insights from thought leaders and experts.

Today’s podcast is sponsored by Cannabis Suisse Corp. (OTC: CSUI)a research & development company licensed under Swiss Cannabis and tobacco regulations to cultivate and sell cannabis. The Company's facilities for producing cannabis are based in Zurich.

The Company grows high quality, organic cannabis with sustainable, all-natural principles. Cannabis Suisse products are laboratory tested to ensure the end users have access to a standardized, safe and consistent product.

In today’s podcast we will be looking at a few public company announcements.

Nextleaf Solutions Ltd. (CSE: OILS) (OTCQB: OILFF), Canada's most innovative cannabis extractor, announced today that it has been issued more patents in North America, Asia, and Europe. These additional patents were awarded in jurisdictions including, but not limited to: the United States; Spain; Portugal; Poland; Malta; Ireland; Denmark; and, Cambodia. These latest issued patents pertain to the Company's unique method of extracting and separating cannabinoids and terpenes.

These patents extend the Company's existing patent portfolio to protect methodologies relating to the removal of fats and waxes during the extraction and purification process, achieving more efficient throughput rates and a higher quality distillate. Less refined cannabis extracts contain chlorophyll, fats, and other impurities that result in undesirable flavours and aromas.

With the latest patent issues, OILS has advanced its intellectual property ("IP") stack to over 35 issued patents, and 65 pending patents, for the industrial-scale extraction, and distillation of cannabinoids. With a 100% pending application to issued patent success rate, the Company has developed defendable IP around the most efficient methods for producing distilled THC and CBD at scale within a regulated environment.

OILS considers European IP protection to be particularly important due to the increasing demand for medical cannabis and CBD products in these rapidly legalizing markets. Prohibition Partners projects the legal European cannabinoid market will be worth more than US$39 billion by 2024, compared to US$37 billion for the more mature North American market by the same time.

The Company's patent portfolio includes protection around the methodologies and technology necessary to efficiently process dried cannabis and hemp biomass into high-purity THC and CBD oils that are used in the manufacturing of cannabinoid formulations and products.

"We expect these patents will have a major impact on the production and sale of standardized cannabinoid-based products in Europe over the twenty year life of the patents," said Paul Pedersen, CEO. "These are jurisdictions that collectively manufacture and export over 70% of all drugs and medicines consumed globally, making European IP protection very important to our long-term global strategy", continued Pedersen.

Valens GroWorks Corp. (TSX: VLNS) (OTCQX: VLNCF), a global leader in the end-to-end development and manufacturing of innovative, cannabinoid-based products, today announced it has entered into a syndicated credit facility with Canadian Imperial Bank of Commerce as Co-Lead Arranger and Administrative Agent, and ATB Financial as Co-Lead Arranger. Under the terms of the credit facility, the Lenders will provide The Valens Company up to C$40 million of secured debt financing.

The Credit Facility consists of a C$20 million secured term loan and a C$20 million secured revolving loan, with an accordion feature that could allow The Valens Company to increase the aggregate commitments by up to an additional C$10 million. The Credit Facility has a three-year term and is secured by a first ranking charge over substantially all the Company's assets.

Proceeds from the Credit Facility will further strengthen the Company's balance sheet, allowing for the continued expansion of its operations and execution of its corporate strategy, including gaining access to new domestic and global opportunities to increase shareholder value.

"Although we are already well capitalized, the Credit Facility increases our financial flexibility and brings down our overall weighted average cost of capital. With our enhanced balance sheet, we are well positioned to continue to expand our innovative product portfolio, build out our custom manufacturing platform, be opportunistic in a consolidating market and maximize capital allocation to generate the highest return on invested capital for our shareholders," said Tyler Robson, CEO of The Valens Company.

General Cannabis Corp. (OTCQX: CANN), the leading publicly traded Colorado cannabis company, announced today that it has reached an agreement that will bring up to $3 million in strategic growth capital to the company.  The investment will be funded by Hershey Strategic Capital LP and Shore Ventures III, LP, entities led by managing member Adam Hershey.

The investment is another important step in General Cannabis’ Colorado-based expansion strategy.  Over the last two months, General Cannabis became only the second publicly traded cannabis company approved by the State of Colorado’s Marijuana Enforcement Division (the “MED”) to acquire licensed cultivation, manufacturing and retail cannabis operations throughout the state of Colorado.  Shortly thereafter, the company closed its acquisition of Boulder, Colorado-based SevenFive Farm, a 17,000 square feet light deprivation greenhouse.  Last week, General Cannabis was conditionally approved by the MED, subject to local approval, to close its next planned acquisition—Pueblo, Colorado-based Cannasseur, a vertically integrated company that commenced operations in 2013 and operates a recreational retail dispensary, a 12,000 square foot light deprivation greenhouse and a manufacturing facility that produces Dabtek, a product line of infused concentrates.  General Cannabis’ Next Big Crop division continues to operate as an industry leader in the application, design, buildout and operation of cultivation facilities, having worked with over 100 cultivation facilities across the country.

Steve Gutterman, CEO of General Cannabis, said: “This significant capital infusion is a powerful statement about our team, our strategy, the market opportunity and our ability to build shareholder value. We are excited to work with Adam Hershey to leverage the extraordinary market opportunity and competitive advantage offered by MED approval and build on the foundation of our SevenFive Farm acquisition and our planned closing of our Cannasseur agreement. Even in the midst of the tremendous headwinds facing our country and the economy, we believe we are as well-positioned as any company in the space to succeed, and this investment is a further demonstration of that. I want to acknowledge the extraordinary group of executives and professionals in our company, including everyone in our NBC division, our finance, accounting and M&A teams and our new colleagues at SevenFive Farm, whose hard work and focus have put General Cannabis in this position to succeed.”

Said Adam Hershey, “As an investor in the cannabis space, we evaluate many potential deals.  General Cannabis, which has a great team and a clear growth path, stood out from the rest.  We couldn’t be more excited to become investors.”

Once again, today’s podcast was sponsored by Cannabis Suisse Corp. (OTC: CSUI)a research & development company licensed under Swiss Cannabis and tobacco regulations to cultivate and sell cannabis. The Company's facilities for producing cannabis are based in Zurich.
The Company grows high quality, organic cannabis with sustainable, all-natural principles. Cannabis Suisse products are laboratory tested to ensure the end users have access to a standardized, safe and consistent product.
Investor ideas reminds all listeners to read our disclaimers and disclosures on the
Investorideas.com website and this podcast is not an endorsement to buy products or services or securities. Investors are reminded all investment involves risk and possible loss of investment   

Learn more about our cannabis podcasts at https://www.investorideas.com/Audio/Potcasts.asp


To hear more Investorideas.com podcasts visit: https://www.investorideas.com/Audio/.
Investorideas.com podcasts are also available on iTunes,  Spotify, Google Play Music, Stitcher, Spreaker,   YouTube via Spreaker,  iHeartradio and Tunein.

Potcasts is now a certified word mark Trademark on the blockchain through Cognate, Inc. CM Certification-Registration Number: 10468217708

About Investorideas.com - News that Inspires Big Investing Ideas
Investorideas.com is a recognized news source publishing third party news, research and original financial content. Learn about investing in stocks and sector trends with our news alerts, articles, podcasts and videos, looking at cannabis, crypto, AI and IoT, mining, sports biotech, water, renewable energy and more. Investor Idea’s original branded content includes the following podcasts and columns : Crypto Corner , Play by Play sports and stock news column, Investor Ideas Potcasts Cannabis News and Stocks on the Move podcast and column,  Cleantech and Climate Change , Exploring Mining  the AI Eye .
Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Contact management and IR of each company directly regarding specific questions. Disclosure: CSUI is a paid monthly cannabis news and social media client More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ and tickertagstocknews.com
Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp

Investor Ideas does not condone the use of cannabis except where permissible by law. Our site does not possess, distribute, or sell cannabis products.


Download our Mobile App for iPhone and Android 

Contact Investorideas.com
800 665 0411







Get more Cannabis Stock Investor Ideas – news, articles, podcasts and stock directory